Long non-coding RNA LINC00649 regulates YES-associated protein 1 (YAP1)/Hippo pathway to accelerate gastric cancer (GC) progression via sequestering miR-16-5p

Hongyan Wang, Xin Di, Yingjie Bi, Shidong Sun, Tao WangBioengineered 2021 · DOI

TL;DR

This study reveals that the long non-coding RNA LINC00649 acts as an oncogene in gastric cancer (GC) by sequestering the microRNA miR-16-5p. This sequestration leads to increased expression of YAP1, dysregulating the Hippo pathway and promoting GC progression, offering potential new targets for diagnosis and treatment.

What Problem Does This Paper Address?

Gastric cancer (GC) remains a significant health challenge, and understanding the molecular mechanisms driving its progression is crucial for developing effective treatments. While long non-coding RNAs (lncRNAs) are increasingly recognized for their roles in various cancers, the specific function of LINC00649 in GC was largely unexplored. Previous studies had linked LINC00649 to other cancers like acute myeloid leukemia and prostate cancer, suggesting a potential oncogenic role. This paper aims to elucidate the specific role of LINC00649 in GC, identify its molecular targets, and understand how it contributes to cancer development, thereby seeking novel diagnostic and therapeutic strategies.

Methods

The researchers employed a multi-pronged approach to investigate LINC00649's role in GC:

  • Expression Analysis: Real-Time quantitative PCR (qPCR) was used to measure the expression levels of LINC00649, miR-16-5p, and YAP1 in both GC tissues and cell lines, as well as in normal counterparts. TCGA data was also utilized for pan-cancer analysis.
  • Gain- and Loss-of-Function Experiments: To assess LINC00649's functional impact, researchers used overexpression and knockdown vectors. They then performed:
  • MTT assay: To evaluate cell proliferation.
  • Trypan blue staining assay: To assess cell viability.
  • Transwell assay: To measure cell migration.
  • Western Blot analysis: To detect protein expression levels of key markers, including N-cadherin, Vimentin (associated with epithelial-mesenchymal transition, EMT), and E-cadherin.
  • Flow cytometry (FCM): To analyze cell apoptosis.
  • In vivo tumorigenesis assay: Using xenograft models in nude mice to observe the effect of LINC00649 on tumor growth.
  • Molecular Mechanism Investigation:
    • Bioinformatic analysis (miRDB, starBase): To predict potential binding targets of LINC00649 and YAP1 mRNA by miR-16-5p.
  • Dual-luciferase reporter gene assay: To validate the direct interaction between miR-16-5p and LINC00649/YAP1.
  • RNA pull-down assay: To confirm the binding of miR-16-5p to LINC00649 and YAP1.
  • Pearson Correlation Analysis: To assess the statistical relationship between the expression levels of LINC00649, miR-16-5p, and YAP1.

Datasets

  • Clinical Specimens: 54 paired cancerous and adjacent non-cancerous tissues from GC patients were collected.
  • TCGA Dataset: Used for pan-cancer analysis of LINC00649 and YAP1 expression in stomach adenocarcinoma (STAD).
  • GC Cell Lines: MGC-803 and SGC-7901 (cancerous) and GES-1 (normal gastric epithelial) cell lines were used.

Key Insights and Ideas

  • LINC00649 as a GC Oncogene: The study provides strong evidence that LINC00649 is significantly upregulated in GC tissues and cells and actively promotes cancer progression by enhancing proliferation, migration, and EMT.
  • miR-16-5p as a Tumor Suppressor: Conversely, miR-16-5p is downregulated in GC and acts as a tumor suppressor, highlighting an antagonistic relationship with LINC00649.
  • The ceRNA Mechanism: LINC00649 functions as a competing endogenous RNA (ceRNA) by sponging miR-16-5p. This is a critical insight, as it explains how LINC00649 can indirectly influence the expression of other genes.
  • YAP1 as a Key Downstream Target: The research establishes that LINC00649's oncogenic effects are mediated through the upregulation of YAP1, a known oncogene implicated in various cancers.
  • YAP1/Hippo Pathway Dysregulation: The study demonstrates that LINC00649, by sequestering miR-16-5p, leads to increased YAP1, which in turn dysregulates the Hippo signaling pathway. This pathway is crucial for maintaining normal cellular functions and suppressing cancer.
  • Downstream Oncogenes: The dysregulated Hippo pathway, driven by LINC00649/miR-16-5p/YAP1, leads to increased expression of downstream oncogenes like EGFR, SOX2, and OCT4, further fueling GC progression.

Key Results

  • LINC00649 and YAP1 mRNA were significantly upregulated in GC tissues and cells compared to normal counterparts, while miR-16-5p was downregulated.
  • LINC00649 overexpression promoted GC cell proliferation and viability, while knockdown had the opposite effect.
  • LINC00649 knockdown suppressed tumor growth in vivo.
  • LINC00649 promoted GC cell migration and EMT, evidenced by increased N-cadherin and Vimentin and decreased E-cadherin.
  • Knockdown of LINC00649 increased cell apoptosis.
  • miR-16-5p directly targeted both LINC00649 and the 3' UTR of YAP1 mRNA.
  • LINC00649 knockdown suppressed YAP1 expression, which was rescued by silencing miR-16-5p, confirming the miR-16-5p-dependent regulation.
  • The effects of LINC00649 knockdown on cell proliferation, viability, migration, and apoptosis were reversed by silencing miR-16-5p or overexpressing YAP1.

Limitations and Future Work

  • Drug Resistance: The authors acknowledge that while their study provides insights into GC progression, future work is needed to investigate the role of these genes in regulating drug resistance in GC.
  • Clinical Utility: While the study identifies potential diagnostic and therapeutic indicators, further clinical validation and translation are necessary for practical application.
  • Broader Impact: The study focuses on specific cell lines and patient samples; exploring the broader implications across diverse GC subtypes and patient populations could be beneficial.

Summary updated

Abstract

Although long non-coding RNA (LncRNA) LINC00649 is reported to be closely associated with acute myeloid leukemia (AML), prostate cancer and colorectal cancer, its role in regulating other types of cancer, such as gastric cancer (GC), has not been studied. This study analyzed the expression status of LINC00649 in GC tissues and cells by performing Real-Time qPCR analysis, and we found that LINC00649 tended to be enriched in cancerous tissues and cells but not in their normal counterparts, which were supported by the data from TCGA dataset. Next, by performing the gain- and loss-of-function experiments, we expectedly found that LINC00649 acted as an oncogene to accelerate GC cell proliferation, migration and epithelial-mesenchymal transition (EMT) <i>in vitro</i> and promote its tumorigenesis <i>in vivo</i>. Moreover, the online miRDB software predicted that miR-16-5p bound to both LINC00649 and 3' untranslated region (3'UTR) of YAP1 mRNA, which were validated by the following dual-luciferase reporter gene system assay and RNA pull-down assay. Finally, we proved that LINC00649 exerted its tumor-promoting effects in GC by regulating the miR-16-5p/YES-associated protein 1 (YAP1)/Hippo pathway. Mechanistically, knock-down of LINC00649 suppressed YAP1 expressions by releasing miR-16-5p, resulting in the recovery of the Hippo pathway, which suppressed the expression levels of the downstream oncogenes, including EGFR, SOX2 and OCT4, leading to the inhibition of the malignant phenotypes in GC cells. In conclusion, this study, for the first time, evidenced that LINC00649 promoted GC progression by targeting the miR-16-5p/YAP1/Hippo signaling pathway, which provided potential diagnostic and therapeutic indicators for GC treatment for clinical utilization.
BibTeX
@inproceedings{wang2021long,
  author = {Hongyan Wang and Xin Di and Yingjie Bi and Shidong Sun and Tao Wang},
  title = {{Long non-coding RNA LINC00649 regulates YES-associated protein 1 (YAP1)/Hippo pathway to accelerate gastric cancer (GC) progression via sequestering miR-16-5p}},
  booktitle = {Bioengineered},
  year = {2021},
  doi = {10.1080/21655979.2021.1924554},
}
Figure